General Information of the Drug (ID: M6APDG04244)
Name
PF-4523655
Status
Phase 2
TTD Drug ID
D0NN5H
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
HIF-1 responsive protein RTP801 (DDIT4)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary HIF-1 responsive protein RTP801 (DDIT4) is a therapeutic target for PF-4523655. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-4523655 through regulating the expression of HIF-1 responsive protein RTP801 (DDIT4). [1], [2]
References
Ref 1 m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021 Nov 9;37(6):109968. doi: 10.1016/j.celrep.2021.109968.
Ref 2 ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia